RxDoctor Payments Data

Jamie Grant, APRN

Nurse Practitioner · Fernandina Beach, FLNPI 1578264578

Payments from drug & device makers

$3,984in general payments, 2019–2025

Across 175 payments — averaging $22.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$433
  • Bayer$417
  • Novartis$382
  • Esperion Therapeutics, Inc.$372
  • Boehringer Ingelheim$278
  • Scpharmaceuticals Inc.$273
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$3,984100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,984 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$7,343
Medicare patients
73
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$125,742
EntrestoSacubitril/Valsartan48$59,481
Repatha SureclickEvolocumab67$49,980
JardianceEmpagliflozin33$40,162
FarxigaDapagliflozin Propanediol38$36,489
XareltoRivaroxaban24$19,703
VascepaIcosapent Ethyl18$18,303
Metoprolol Succinate137$1,733
Ezetimibe76$1,418
Rosuvastatin Calcium109$1,243
Ranolazine ErRanolazine23$1,178
Atorvastatin Calcium96$808
Spironolactone69$570
Amlodipine Besylate91$570
Valsartan20$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$255$125,742100 claims
NovartisEntresto$382$59,48148 claims
Boehringer IngelheimJardiance$278$40,16233 claims
AstraZenecaFarxiga$172$36,48938 claims
Johnson & JohnsonXarelto$65$19,70324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Fernandina Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →